Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus SPECTAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus SPECTAZOLE.
GRIS-PEG vs SPECTAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing cell membrane permeability.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
Apply a thin layer to affected area once daily for 4-4 weeks; duration depends on indication.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Terminal elimination half-life is approximately 24-30 hours in patients with normal renal function, allowing once-daily dosing.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Primarily renal: approximately 70% of an oral dose is excreted unchanged in urine; biliary/fecal excretion accounts for ~20%, with the remainder as metabolites.
Category C
Category C
Antifungal
Antifungal